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Heterobimetallic propargyl gold complexes
with π-bound copper or silver with enhanced
anticancer activity†
Alice Johnson, a Isabel Marzob and M. Concepción Gimeno *a
Several propargyl functionalised substrates with different heteroatoms (N, O or S) have been used for the
preparation of propargyl gold(I) phosphine complexes. The complexes were prepared in high yields either
by reaction of the substrate with [Au(acac)PPh3] or by reaction of [AuCl(PPh3)] with potassium hydroxide
and the substrate in methanol. Several of the complexes have been characterised by X-ray diffraction
showing the presence of secondary bonds such as π-stacking and aurophilic interactions. The reaction of
the propargyl gold(I) phosphine complexes with [Cu(NO3)(PPh3)2] or [Ag(OTf)(PPh3)2] afforded heterobi-
metallic complexes with π-coordination of {Cu(PPh3)2} or {Ag(PPh3)2} to the alkyne bond. When the sub-
stituent of the propargyl unit contained more strongly coordinating pyridine moieties,
[(PyCH2)2NCH2CuCAuPPh3], coordination of the heterometal to the pyridine units occurred, displacing
the phosphine groups and giving rise to a dimeric structure. The antiproliferative activity of the complexes
against cisplatin resistant lung cancer cell line A549 was determined by MTT assay. The mononuclear gold
complexes showed excellent activities with IC50 values < 14 μM. Coordination of copper of silver to the
alkynyl fragment resulted in a significant increase in activity suggesting a synergistic effect between the
two metal centres.
Introduction
Following the serendipitous discovery of the anticancer activity
of cisplatin over 50 years ago1 and its subsequent approval by
the FDA for the treatment of cancers in 1978, there has been
increasing interest in the use of transition metal complexes in
cancer treatments. Despite the success of the platinum com-
plexes, there are several known side-effects and increasing
reports of cisplatin resistant cancers and hence considerable
research is now focussed on other metals. Interest in gold(I)
complexes initially arose as a result of the anti-rheumatic drug
Auranofin (Fig. 1(a)) which has shown potent anticancer
activity.2 Gold(I) has not only been shown to be better tolerated
in vivo than platinum, but the mechanism of action is signifi-
cantly different since gold(I) targets cellular enzymes rather
than DNA.3,4 Of the gold(I) complexes reported to have anti-
cancer activity, alkynyl–gold(I)–phosphine complexes are
among the most potent.5–14
The incorporation of a second different metal centre into a
complex can alter the physiochemical properties significantly.
This can be advantageous in the development of chemothera-
Fig. 1 (a) Auranofin, (b) Au(I)–Cu(I) complexes reported by Laguna [PTA
= 1,3,5-Triaza-7-phosphaadamantane, DAPTA = 3,7-diacetyl-1,3,7-
triaza-5-phosphabicyclo[3.3.1]nonane],16 (c) Au(I)–Ag(I) complexes
reported by Couce [R = phenyl, 2-chlorophenyl, 3-methoxyphenyl,
3-hydroxyphenyl, 2-furyl, 2-thienyl],17 (d) this work.
†Electronic supplementary information (ESI) available. CCDC 2009440–2009446.
For ESI and crystallographic data in CIF or other electronic format see DOI:
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peutic agents as a means of enhancing cytotoxicity. In these bi-
metallic compounds, where both metals could be cytotoxic via
different mechanisms of action, there is the possibility for a
synergistic effect due to the interaction with multiple biologi-
cal targets, modulation in redox properties and/or changes in
compound stability that could result in the improvement of
the antitumor activity in comparison with the mononuclear
precursors.15
There have been several reports of heterometallic complexes
exhibiting such a synergistic effect between the metal centres,
and the presence of two metal centres which display cytotoxic
activity through different mechanisms of action can also
prevent resistance occurring. However, there have been very
few reported studies of the anticancer activity of heterometallic
complexes of the coinage metals. Laguna and co-workers
reported the anticancer activity of four Au(I)–Cu(I) complexes
(Fig. 1(b)) which all had IC50 values in the nanomolar range,
significantly lower than cisplatin or Auranofin when tested
under the same conditions. Although the mechanism of
action of the heterometallic complexes was not fully under-
stood the authors suggested that the complexes achieved the
correct balance of hydrophilicity and lipophilicity to maximise
the cytotoxicity.16 The only reported cytotoxic Au(I)–Ag(I) het-
erometallic complexes to date are a series of 3-(aryl)-2-sulfanyl-
propenoic acid derivatives reported by Couce and co-workers
(Fig. 1(c)). The complexes exhibited greater cytotoxicity in the
cervical cancer cell line A2780cisR, however no mechanistic
studies were carried out.17 In general, the studies carried out
with bimetallic complexes highlight that anti-proliferative pro-
perties are mainly driven by the most cytotoxic metal.
However, the cooperative effect and synergism may be
observed in metal-specific interactions with distinct biological
targets or by improvement of the physicochemical properties
of the final compounds.18
The π-coordination of a Cu(PPh3)2 or Ag(PPh3)2 group to an
alkynyl–gold complex has previously been explored as a means
of enhancing the luminescence.19,20 Such complexes can
readily be synthesised and are known to be highly stable,
however despite this their potential biological application has
not been explored. Here were report the synthesis of a series of
propargyl–Au(I)–PPh3 complexes and study their anticancer
activity in a cisplatin resistant cancer cell line, A549. We then
show how the alkyne bond can provide a coordination site for




Propargyl functionalised substrates with different heteroatoms
were chosen for the preparation of propargyl gold(I) phosphine
complexes.
Propargyl gold(I) triphenylphosphine complexes 1–8
could be prepared by two different methods (Scheme 1).
Addition of [Au(acac)(PPh3)] to a solution of the propargyl
substrate in dichloromethane led to the formation of the
complexes which could be isolated by concentration of the
reaction solution and precipitation with diethyl ether, and
were obtained in good yields (48–99%).† Alternatively, the
products could be prepared by the addition of [AuCl(PPh3)]
and potassium hydroxide to a solution of the substrate in
methanol. This method avoids the need to prepare the acac
gold(I) precursor and the products are obtained with high
purity since they precipitate from the reaction solution,
however, in most cases the yields were lower (12–91%). All of
the complexes were isolated as air-stable white solids.
Successful reaction could be confirmed by the dis-
appearance of the propargyl CH signal in the 1H NMR
spectra, and the 31P NMR spectra all showed a sharp signal
at around 42 ppm, a typical value for a triphenylphosphine
group bound to gold(I) trans to a carbon-based ligand.
Complex 1 was found to be unstable in solution in dichloro-
methane, slowly converting into another product as observed
Scheme 1 Synthesis of complexes 1–8.
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by NMR studies (see ESI†). This is likely to be a dimeric or oli-
gomeric species as a result of coordination of the sterically
unhindered amine group to the gold centre. Complexes 2–8
were all stable in solution for at least 24 h.
The nitrogen based propargyl derivatives 2–4 were charac-
terised by single crystal X-ray diffraction (Fig. 2). In all cases
the propargyl bond distances are typical of those expected for
triple and single C–C bonds. An almost linear geometry is
observed about the gold centres and the trans influence of the
phosphine ligand results in relatively long Au–C bonds. The
Au–C distances are Au(1)–C(1) 2.024(5) Å for 2, Au(1)–C(1)
2.0004(18) Å for 3, and Au(1)–C(1) 1.997(3) Å for 4.
Complexes 3 and 4 have a structure in which the molecules
are arranged in dimers as a result of π-stacking interactions.
For complex 3 the six-membered ring of the carbazole unit of
one molecule lies over the five-membered ring of the carbazole
unit of another molecule with intermolecular distances cen-
troid–centroid 3.551 Å and C(7)–N(1)′ 3.546 Å observed (Fig. 3).
For complex 4 a slipped π-stacking interaction between the
benzotriazole rings with a distance of 3.654 Å is also observed
(see ESI†).
The structure of the propargyl ether and thioether gold
complexes 5 and 8 is shown in Fig. 4. The general bond
lengths and angles are similar to those found in the complexes
above. The Au–C distances are 2.005(5) for 5, 2.060(9) for 7
(Fig. 4) or 1.994(3) Å for 8.
The dinuclear complex 7 is the only compound to display
intermolecular aurophilic interactions in the solid state. This
results in the molecules being associated in chains with an
intermolecular Au–Au distance of 3.2907(4) Å (Fig. 5).
Reaction of complex 2 with one equivalent of [Cu(NO3)
(PPh3)2] in dichloromethane gave the dimeric complex 9
(Scheme 2). The copper successfully binds to the alkyne bond
of the propargyl unit and the triphenylphosphine ligands at
the copper centre are displaced by the nitrogen donor pyridine
and amine groups. The analogous reaction with [Ag(OTf)
(PPh3)] led to a mixture of products due to the stronger affinity
of the silver centre for phosphine over nitrogen ligands.
Complex 9 was characterised by single crystal X-ray diffrac-
tion. The molecule lies in a symmetry centre and only half of
the molecule corresponds to the asymmetric unit (Fig. 6).
Coordination of the copper to the alkyne triple bond results in
a lengthening of the bond to 1.233(4) Å compared to 1.173(7) Å
for complex 2. The copper coordinates to the centre of the
alkyne triple bond with distances Cu(1)–C(1) 2.019(2) Å and
Cu(1)–C(2) 2.004(2) Å. In addition, the Au(1)–C(1) bond is
1.999(3) Å, which is very similar to that in the starting complex
2 suggesting that coordination of the copper fragment does
not significantly affect the strength of the gold–carbon bond.
There are two short Cu–N bonds, with lengths Cu(1)–N(1)
2.033(2) Å and Cu(1)–N(3) 2.017(2) Å to the nitrogens of the
Fig. 2 Molecular structures of complexes 2 and 4 determined by single
crystal X-ray diffraction. Selected bond lengths [Å] and angles [°] 2:
Au(1)–C(1) 2.024(5), Au(1)–P(1) 2.2711(13), C(1)–C(2) 1.173(7), C(2)–C(3)
1.487(8), C(1)–Au(1)–P(1) 178.95(15), C(1)–C(2)–C(3) 176.6(6); 4: Au(1)–
C(1) 1.997(3), Au(1)–P(1) 2.2772(8), C(1)–C(2) 1.198(4), C(2)–C(3) 1.468(4),
C(1)–Au(1)–P(1) 175.31(8), C(1)–C(2)–C(3) 178.7(3).
Fig. 5 Molecular structure of complex 7 determined by single crystal
X-ray diffraction showing intermolecular aurophilic interactions.
Selected bond lengths [Å] and angles [°]: Au(1)–C(1) 2.060(9), Au1–C1B
1.951(9), Au(1)–P(1) 2.2733(12), Au(1)–Au(1)#1 3.2907(4), C(1)–C(2)
1.205(2), C(2)–C(3) 1.439(2), C(1)–Au(1)–P(1) 168.0(7), C(1)–C(2)–C(3)
177.6(18). In complex 7 the oxygen atom is disordered, only distances to
the main component are included.
Fig. 3 Molecular structures of complex 3 determined by single crystal
X-ray diffraction showing π-stacking interactions. Selected bond lengths
[Å] and angles [°]: Au(1)–C(1) 2.0004(18), Au(1)–P(1) 2.2686(8), C(1)–C(2)
1.200(2), C(2)–C(3) 1.472(2), C(1)–Au(1)–P(1) 175.56(5), C(1)–C(2)–C(3)
173.60(17), Centroid(1)–Centroid(2) 3.551, C(7)–N(1)’ 3.546.
Fig. 4 Molecular structures of complexes 5 and 8 determined by single
crystal X-ray diffraction. Selected bond lengths [Å] and angles [°] 5:
Au(1)–C(4) 2.005(5), Au(1)–P(1) 2.2870(12), O(1)–C(1) 1.393(7), O(1)–C(2)
1.416(6), C(2)–C(3) 1.489(7), C(3)–C(4) 1.205(7), C(4)–Au(1)–P(1)
178.38(15), C(4)–C(3)–C(2) 174.4(5); 8: Au(1)–C(1) 1.994(3), Au(1)–P(1)
2.2766(7), S(1)–C(4) 1.763(3), S(1)–C(3) 1.818(4), C(1)–C(2) 1.206(4), C(2)–
C(3) 1.467(4), C(1)–Au(1)–P(1) 173.51(9), C(1)–C(2)–C(3) 175.1(3).
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pyridyl groups, and one longer Cu(1)–N(2) 2.264(2) Å to the
amine nitrogen. The coordination about the gold centre is
slightly distorted from linearity due to steric hindrance
between the bulky triphenylphosphine ligand and the pyridyl
groups with an angle P(1)–Au(1)–C(1) 171.15(7)°. The propargyl
angle is considerably distorted from linearity as a result of the
coordination of the copper, with an angle C(1)–C(2)–C(3)
160.1(3)°. The Cu(1)–Au(1) distance of 3.535 Å is too long to
indicate the presence of any metallophilic interaction between
the two metal centres.
The 31P NMR spectrum of 9 displays a broad signal at room
temperature, indicative of a fluxional process, however at 193 K
this signal becomes a sharp singlet and the protons of the
CH2Py groups become inequivalent, in agreement with the
solid-state structure.
Complexes 10–19 were prepared by reaction of mononuclear
gold complexes 3–6 and 8 with [Cu(NO3)(PPh3)2] or [Ag(OTf)
(PPh3)2] (Scheme 3). In these complexes the copper or silver
binds to the alkyne triple bond, maintaining the two triphenyl-
phosphine ligands. The identity of 10–19 can be confirmed by
NMR studies. The 1H NMR spectra show additional aromatic
protons for the triphenylphosphine ligands and two broad
peaks are observed in the 31P{1H} NMR spectra.
Biological activity
Complexes 2–19 were not soluble in water but were soluble in
DMSO and mixtures of DMSO/water used to carry out the tests.
Stability studies have been done for the mononuclear com-
plexes in DMSO by 1H NMR (Fig. S1–S9†) and the bimetallic
complexes were tested in DMSO/PBS by UV-vis spectroscopy
(Fig. S10–S16†) for a period of 24 h. No changes were observed
between the initial 1H NMR or UV-vis spectra and the corres-
ponding ones after 24 h, confirming the retention of the com-
plexes in solution. The biological activity of the complexes was
studied by MTT assay for lung carcinoma cell line A549. The
calculated IC50 values for the complexes after 24 h incubation
are shown in Table 1.
The carbazole derivative, complex 3, was the only complex
not to show any antiproliferative activity against A549 cells at
the concentrations tested with IC50 value of >100 μM. The
other monometallic gold complexes (2, 4–6 and 8) showed
excellent IC50 values for 24 h incubation with the cancer cells.
No significant differences are observed upon changing the
heteroatom of the propargyl substrate as all of the IC50 values
are within a similar range 9–13 μM, the sulfur derivative, 8,
having the lowest IC50 value of the gold triphenylphosphine
complexes at 9.11 ± 1.93 μM. Dinuclear gold triphenyl-
phosphine complex 7, derivative of dipropargylether did not
show a greater activity than the mononuclear propargylether
derivatives 5 and 6. There therefore appears to be no corre-
lation between the number of gold-triphenylphosphine units
in the complex and the overall activity. A comparison with the
cytotoxicity of the reference cisplatin complex in the same con-
ditions, 114.2 ± 9.1 µM,21 although measured in water,
revealed a much higher activity for the gold complexes.
Fig. 6 Molecular structure of complex 9 determined by single crystal
X-ray diffraction. Selected bond lengths [Å] and angles [°]: Au(1)–C(1)
1.999(3), Au(1)–P(1) 2.2694(6), Cu(1)–C(2) 2.004(2), Cu(1)–N(3) 2.017(2),
Cu(1)–C(1) 2.019(2), Cu(1)–N(1) 2.033(2), Cu(1)–N(2) 2.264(2), C(1)–C(2)
1.233(4), C(2)–C(3) 1.479(3), C(1)–Au(1)–P(1) 171.15(7), C(2)–Cu(1)–N(3)
106.54(9), C(2)–Cu(1)–C(1) 35.70(10), N(3)–Cu(1)–C(1) 142.18(9), C(2)–
Cu(1)–N(1) 142.73(9), N(3)–Cu(1)–N(1) 109.17(8), C(1)–Cu(1)–N(1)
108.27(9), C(2)–Cu(1)–N(2) 116.78(9), N(3)–Cu(1)–N(2) 80.69(8), C(1)–
Cu(1)–N(2) 111.27(9), N(1)–Cu(1)–N(2) 79.63(8), C(1)–C(2)–C(3) 160.1(3).
Scheme 3 Synthesis of heterometallic complexes 10–19.
Scheme 2 Synthesis of complex 9.
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The introduction of the π-bound copper(I) or silver(I) ion
had a huge effect on the antiproliferative activity of the com-
plexes. In all cases the IC50 values were considerably lower,
most notable for the carbazole derivatives where the gold
complex 3 showed no activity but the gold–copper and gold–
silver heterobimetallic complexes 10 and 15 did have antiproli-
ferative activity. In all cases the derivatives with silver had
slightly lower IC50 values than their copper analogues. It is
also worth noting that other than with the carbazole deriva-
tives, the heterometallic complexes all had IC50 values lower
than the control compounds [Cu(NO)3(PPh3)2] or [Ag(OTf)
(PPh3)2], therefore the combination of two metals, Au and Cu/
Ag, is more potent than either complex separately.
Experimental section
Experimental details
Mass spectra were recorded on a BRUKER ESQUIRE 3000
PLUS, with the electrospray (ESI) technique. 1H, 13C{1H} and
31P NMR, including 2D experiments, were recorded at room
temperature on a BRUKER AVANCE 400 spectrometer (1H,
400 MHz, 13C, 100.6 MHz, 31P, 162 MHz) or on a Bruker
Avance II 300 spectrometer (1H 300.0 MHz, 13C 75.5 MHz, 31P
121.5 MHz, 19F 282.3 MHz), with chemical shifts (δ, ppm)
reported relative to the solvent peaks of the deuterated solvent.
Infrared spectra were recorded in the range 4000–250 cm−1 on
a PerkinElmer Spectrum 100 FTIR spectrometer.
Crystal structure determinations
Crystals were mounted in inert oil on glass fibres and trans-
ferred to the cold gas stream of an Xcalibur Oxford Diffraction
(2) or a Smart APEX CCD diffractometers (3–5, 7, 8) equipped
with a low-temperature attachment. Data were collected using
monochromated MoKα radiation (λ = 0.71073 Å). Scan type ϖ.
Absorption corrections based on multiple scans were applied
using SADABS22 or spherical harmonics implemented in
SCALE3 ABSPACK scaling algorithm.23 The structures were
solved by direct methods and refined on F2 using the program
SHELXT-2016,24 or and by using Olex2 as the graphical inter-
face.25 All non-hydrogen atoms were refined anisotropically.
CCDC deposition numbers 2009440 (2), 2009441 (3), 2009442
(4), 2009443 (5), 2009444 (7), 2009445 (8) and 2009446 (9)
contain the supplementary crystallographic data.†
Materials and procedures






(2-picolyl)amine31 and N-propargylcarbazole32 were prepared
according to published procedures. All other reagents were com-
mercially available and were used without further purification.
Solvents were dried with a SPS solvent purification system.
Cell culture
A549 (human lung carcinoma) cells were maintained in high
glucose DMEM (Dulbecco’s Modified Eagle’s Medium) sup-
plemented with 5% fetal bovine serum (FBS), 200 μg mL−1
penicillin, 100 µg mL−1 streptomycin and 2 mM L-glutamine.
Antiproliferative studies: MTT assay
Exponentially growing cells (A549) were seeded at a density of
approximately 104 cells per well in 96 well flat-bottomed micro-
plates and allowed to attach for 24 h prior to addition of com-
pounds. Various concentrations of the compounds
(0.1–100 μM) were added and incubated for 24 h at 37 °C (total
volume 200 μl). Stock solutions of the compounds were pre-
pared as 10 mM DMSO solutions and diluted using DMEM
media. The final concentration of DMSO in each well was
≤0.25%. After 24 h, 10 μl of MTT (5 mg ml−1 in PBS) was
added to each well and the plates incubated for an additional
2 h at 37 °C. The media/MTT mixture was eliminated and
DMSO (100 μl per well) was added to dissolve the formazan
precipitates. The optical density was measured at 550 nm
using a 96-well multiscanner autoreader (ELISA). Absorbance
values were normalised to (DMSO-containing) control wells
and plotted as concentration of compound versus % cell viabi-
lity. IC50 values were calculated by nonlinear regression ana-
lysis. The reported IC50 values are the average of three indepen-
dent experiments, each consisting of four replicates per con-
centration level (overall n = 12).
General synthesis of [Au(CuCCH2R)(PPh3)] via [Au(acac)
(PPh3)]
To a solution of the corresponding HCuCCH2R (0.1 mmol) in
CH2Cl2 (5 ml) was added [Au(acac)(PPh3)] (0.0559 g, 0.1 mmol)
Table 1 IC50 Values for complexes 2–19, [Cu(NO3)(PPh3)2] and [Ag(OTf)(PPh3)2] after 24 h incubation with A549 cells
Au complex IC50 (μM) Au–Cu complex IC50 (μM) Au–Ag complex IC50 (μM)
2 13.32 ± 0.51 9a 1.37 ± 0.21
3 >100 10 6.16 ± 0.18 15 4.92 ± 0.04
4 11.91 ± 1.54 11 2.50 ± 0.19 16 1.19 ± 0.03
5 10.27 ± 0.76 12 1.78 ± 0.18 17 1.44 ± 0.13
6 10.61 ± 0.93 13 1.60 ± 0.18 18 1.08 ± 0.12
7 12.28 ± 2.66
8 9.11 ± 1.93 14 1.64 ± 0.10 19 1.44 ± 0.13
[Cu(NO3)(PPh3)2] 4.17 ± 0.19 [Ag(OTf)(PPh3)2] 2.54 ± 0.26
a Value for the mononuclear complex.
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and the solution stirred for 2 h. The solution was filtered
through Celite, the filtrate concentrated under reduced
pressure to approximately 1 ml and Et2O added to precipitate a
solid of the corresponding compound.
General synthesis of [Au(CuCCH2R)(PPh3)] via [AuCl(PPh3)]
and KOH
To a solution of the corresponding HCuCCH2R (0.2 mmol) in
MeOH (15 ml) was added [AuCl(PPh3)] (0.0989 g, 0.2 mmol)
and KOH (0.0168 g, 0.3 mmol) and the mixture stirred for 12 h.
A white precipitate formed which was collected, washed with
Et2O and vacuum dried to give the corresponding product.
General synthesis of heterometallic complexes
To a solution of the corresponding gold complex (0.2 mmol) in
dichloromethane (5 ml) was added [Cu(NO3)(PPh3)2] (0.1300 g,
0.2 mmol) or [Ag(OTf)(PPh3)2] (0.1563 g, 0.2 mmol) and the
solution stirred for 1 h. The solution was concentrated under
reduced pressure to approximately 1 ml and hexane (10 ml)
added to precipitate a solid of the corresponding compound.
Conclusions
We have prepared and characterised new propargyl gold tri-
phenylphosphine complexes bearing different functional
groups and tested the anticancer activity of these in A549 cells.
The propargyl gold compounds could be prepared by two
different methods: addition of [Au(acac)(PPh3)] to a solution of
the substrate in dichloromethane, or reaction of the substrate
with potassium hydroxide and [AuCl(PPh3)] in methanol,
however the “acac” method generally resulted in higher yields.
Several derivatives were structurally characterised by single
crystal X-ray diffraction with intermolecular contacts observed.
Heterometallic dinuclear gold(I) complexes with copper(I)
and silver(I) were also prepared in which the copper or silver is
bound to the triple bond of the propargyl unit.
We have for the first time used the alkyne bond to incorpor-
ate an additional metal centre into the complex in order to
directly compare the antiproliferative activity of gold–copper
and gold–silver heterobimetallic complexes. The use of the
propargyl gold complexes as a tether for the cytotoxic copper
or silver centres gave improved activities compared to the
copper or silver starting complexes or the mononuclear gold
complexes, suggesting a possible synergy between the two
metal centres within the cell.
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